Tibet Cheezheng Tibetan Medicine Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 37.31%

Tibet Cheezheng Tibetan Medicine Co Ltd (002287) has an Asset Resilience Ratio of 37.31% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Tibet Cheezheng Tibetan Medicine Co Ltd (002287) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥2.48 Billion

≈ $363.43 Million USD Cash + Short-term Investments

Total Assets

CN¥6.66 Billion

≈ $974.13 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Tibet Cheezheng Tibetan Medicine Co Ltd's Asset Resilience Ratio has changed over time. See Tibet Cheezheng Tibetan Medicine Co Ltd (002287) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Tibet Cheezheng Tibetan Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002287 stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥2.48 Billion	37.31%
Total Liquid Assets	CN¥2.48 Billion	37.31%

Asset Resilience Insights

Very High Liquidity: Tibet Cheezheng Tibetan Medicine Co Ltd maintains exceptional liquid asset reserves at 37.31% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Tibet Cheezheng Tibetan Medicine Co Ltd Industry Peers by Asset Resilience Ratio

Compare Tibet Cheezheng Tibetan Medicine Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Tibet Cheezheng Tibetan Medicine Co Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Tibet Cheezheng Tibetan Medicine Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	37.18%	CN¥2.57 Billion ≈ $376.34 Million	CN¥6.92 Billion ≈ $1.01 Billion	-4.16pp
2024-12-31	41.34%	CN¥2.81 Billion ≈ $410.80 Million	CN¥6.79 Billion ≈ $993.65 Million	+10.18pp
2023-12-31	31.17%	CN¥1.96 Billion ≈ $287.26 Million	CN¥6.30 Billion ≈ $921.67 Million	+5.02pp
2022-12-31	26.15%	CN¥1.54 Billion ≈ $225.25 Million	CN¥5.89 Billion ≈ $861.40 Million	+4.88pp
2021-12-31	21.26%	CN¥1.18 Billion ≈ $173.25 Million	CN¥5.57 Billion ≈ $814.74 Million	+20.18pp
2019-12-31	1.08%	CN¥32.28 Million ≈ $4.72 Million	CN¥2.98 Billion ≈ $436.67 Million	-17.94pp
2018-12-31	19.02%	CN¥440.00 Million ≈ $64.39 Million	CN¥2.31 Billion ≈ $338.43 Million	+0.69pp
2017-12-31	18.33%	CN¥421.00 Million ≈ $61.61 Million	CN¥2.30 Billion ≈ $336.06 Million	+8.70pp
2016-12-31	9.64%	CN¥200.00 Million ≈ $29.27 Million	CN¥2.08 Billion ≈ $303.74 Million	-3.41pp
2015-12-31	13.04%	CN¥270.00 Million ≈ $39.51 Million	CN¥2.07 Billion ≈ $302.93 Million	-5.76pp
2014-12-31	18.81%	CN¥337.00 Million ≈ $49.31 Million	CN¥1.79 Billion ≈ $262.21 Million	--

pp = percentage points

About Tibet Cheezheng Tibetan Medicine Co Ltd

SHE:002287 China Biotechnology

Market Cap

$1.64 Billion

CN¥11.22 Billion CNY

Market Cap Rank

#7004 Global

#1579 in China

Share Price

CN¥19.61

Change (1 day)

-0.96%

52-Week Range

CN¥19.61 - CN¥35.78

All Time High

CN¥1299.72